Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 10/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.76 |
| ▸ | ITGB8 | P26012 | 10/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422511 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6422506 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6107608 | 0.97 | ITGAV (0.94) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6107292 | 0.97 | ITGAV (0.94) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6107289 | 0.97 | ITGAV (0.94) | ITGAVITGB3ITGB6ITGB8 | |
| Trifluoroacetic Acid SCHEMBL6422659 | 0.95 | ITGAV (0.90) | ITGAVITGB3ITGB6ITGB8 | |
| Trifluoroacetic Acid SCHEMBL6421286 | 0.95 | ITGAV (0.90) | ITGAVITGB3ITGB6ITGB8 | |
| Trifluoroacetic Acid SCHEMBL6422214 | 0.95 | ITGAV (0.90) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6421258 | 0.91 | ITGAV (0.83) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6357539 | 0.91 | ITGAV (0.83) | ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | claimed |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2005-01-06 | — | — | US | claimed |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | HARTMAN GEORGE D (US) | 2004-03-18 | — | — | US | claimed |
| EP-1322311-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2002-04-04 | — | — | US | claimed |
| WO-2002022124-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | claimed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2016154369-A1 | COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2005-01-06 | — | — | US | disclosed |
| US-20020040030-A1 | Alpha V integrin receptor antagonists | COLEMAN PAUL J (US) | 2002-04-04 | — | — | US | disclosed |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2002-04-04 | — | — | US | disclosed |
| WO-2002022124-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040030-A1 | Alpha V integrin receptor antagonists | VCAM1, ITGAV, ITGB1 | ITGAV 2/4885ITGB3 5/4885ITGB6 19/4885 |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | ITGAM, ITGAL, ITGB1 | ITGAV 9/4885ITGB3 8/4885ITGB6 27/4885 |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | ITGAV 5/4885ITGB3 9/4885ITGB6 24/4885 |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGA2 | ITGAV 1/4885ITGB3 9/4885ITGB6 15/4885 |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGB5 | ITGAV 1/4885ITGB3 8/4885ITGB6 13/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | ITGAV 1/4885ITGB3 2/4885ITGB6 9/4885 |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | ITGB3, ITGB5, ITGB2 | ITGAV 11/4885ITGB3 1/4885ITGB6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.